Capricor Therapeutics CAPR Business Segments — Interest Expense Nonoperating
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Capricor Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The official record: Capricor Therapeutics’s 10-K, filed March 17, 2026, on SEC EDGAR. View the filing →
Ask your AI about Capricor Therapeutics's business segments — interest expense nonoperating.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Capricor Therapeutics's business segments — interest expense nonoperating?
- Capricor Therapeutics (CAPR) reported business segments — interest expense nonoperating of $761.43K in Q4 2025.
- What does business segments — interest expense nonoperating mean?
- This reflects the costs incurred by the company for servicing debt or other financial obligations that are not part of core operating expenses. It indicates the company's reliance on external financing and the associated cost of capital. High interest expenses can significantly impact the net cash position of a development-stage company.